News

Opinion
Zacks Investment Research on MSN4hOpinion
Bull of the Day: Hims & Hers Health (HIMS)
Hims & Hers Health (HIMS) is quickly becoming one of the most compelling stories in the market as an emerging powerhouse in the direct-to-consumer healthcare space. The stock has posted outsized gains ...
A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a ...
Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least ...
BENGALURU] European shares closed lower on Friday (Jul 11), as losses in banks and healthcare stocks weighed at the end of a ...
In a recent panel conversation, healthcare and industry experts discussed where to find reliable guidance in a sea of ...
Wockhardt announces its exit from the US generics market, shifting focus to its innovative antibiotic and biologicals ...
Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...
One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.